Healthcare organisations are expanding artificial intelligence use faster than internal controls can manage. Last year, the share of health organisations implementing domain-specific AI tools increased sevenfold. Vendor activity has intensified and pilot programmes have multiplied, while clinical and administrative teams deploy tools to address local problems. In many cases, no one tracks what enters use, where it operates or why it was selected. That gap creates a governance issue with direct relevance to patient data, clinical workflows and regulatory standing. When AI tools operate without inventory, ownership and monitoring, a single deployment can affect multiple areas of organisational risk before a problem becomes visible.
AI Sprawl Creates Visibility Gaps
AI sprawl often begins with a practical operational need. A team identifies a problem, selects a tool and finds that it works well enough for wider use. Over time, the tool spreads across departments and becomes embedded in routine activity. It may touch patient data, influence clinical decisions or generate outputs without formal review. The absence of a defined process allows governance gaps to develop even when the initial deployment is limited in scope.
The central issue is inventory. Without a current and accurate list of AI systems in the organisational environment, risk posture cannot be assessed. Every unvetted tool expands the attack surface, and the risk is self-inflicted when deployment happens without review. Shadow AI also differs from the shadow IT problem already familiar to many security teams. An unsanctioned software-as-a-service tool may be containable, but AI tools outside formal frameworks can create risks through algorithmic drift, bias and compounding errors.
Must Read: Clinical AI Needs Governance Beyond Pilot Projects
Those failures may remain hidden until a large number of decisions have already been affected. In healthcare, unmanaged AI can contribute to delayed or incorrect diagnoses, biased treatment recommendations and data exposures that lead to regulatory action. A tool that is not tracked can become a serious organisational exposure.
Risk Assessment Cannot Stop at Deployment
The pressure to move quickly is understandable in resource-constrained healthcare environments. Pilot programmes are often treated as low-stakes, and additional process can seem easy to defer. However, speed and skipped governance steps are not the same. AI deployment requires basic questions before use begins: what the tool does, what data it accesses, who owns it, which decisions it informs and what happens when it fails or produces a false output.
Those questions mirror the checks that security and operations teams would apply to any significant system. AI tools entering through informal channels should not bypass that scrutiny. A tool that clears review at the start also requires continued oversight. Safety on day one does not guarantee safety months later. Models may drift from their original context or alignment, vendors may introduce updates that disrupt systems and regulatory requirements may change.
Vendor exposure adds further pressure. More than 700 large healthcare data breaches are reported each year, and third-party vendors consistently rank among the main sources of data exposure. Every AI vendor therefore represents a third-party relationship. AI tools need ongoing monitoring, clear contractual expectations and an accountable organisational owner responsible for addressing problems when systems fail.
Governance Practices Already Exist
Healthcare organisations already have many of the processes needed to manage AI more effectively. The immediate task is to apply them consistently to AI tools. Inventory comes first. Organisations need to ask teams which AI tools they use, including free tools, consumer applications used for work and any system that touches patient data or clinical workflows. In many organisations, the real scale of AI use exceeds what leadership believes.
Once the inventory exists, classification becomes essential. A scheduling assistant and a clinical decision-support tool do not carry the same risk and should not undergo identical evaluation. Triage should reflect potential impact, with scrutiny scaled to the level of risk. Ownership must also be explicit. Every AI deployment needs an accountable owner, responsible not only for the vendor relationship but also for monitoring performance and identifying changes over time.
Monitoring should be built in from the beginning. Organisations need to define what a strong deployment looks like and schedule formal checkpoints to verify integrity. Those requirements belong both in vendor contracts and in internal expectations. Shared sector resources can also support governance work, including frameworks, risk assessment templates and operational lessons developed through collaboration across healthcare organisations.
Healthcare AI adoption is not slowing, and new tools continue to enter the market. Each month without a governance framework adds more unvetted tools, unmonitored vendors and poorly supervised decision systems to the healthcare environment. Strong governance models allow organisations to scale AI more effectively, safely and with less exposure. The central issue is not whether healthcare should move quickly with AI, but whether its technology stack and oversight processes can withstand the pressure created by rapid deployment.
Source: Next Tech Today
Image Credit: iStock
